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At last, following decades of research endeavor, clinical
success is here. A new molecular classification and novel
targeted therapy can improve poor oncological outcomes of
some patients with gastric cancer.
Each year 900,000 patients are diagnosed worldwide
with gastric cancer. Potentially, approximately 25% of
these patients may benefit by adding trastuzumab to current
standard treatment. Why and what is the new molecular
classification crucial for this therapeutic decision? What
are the limitations of this monoclonal antibody, and how
could intrinsic and acquired resistance be overcome?
Despite optimization of surgery, radiotherapy, and cyto-
toxic chemotherapy, survival of advanced gastric cancer is
poor. Five years after this multimodal treatment, \40% of
Western patients with stage II or III disease are alive. In
metastatic stage IV, mean survival is only 10 months.
Most promise to improve this poor survival is provided
by biologically targeted agents. The concept is exciting.
Suppression of deregulated signaling pathways which play
a central role in cell proliferation, survival, apoptosis, and
angiogenesis may be a highly effective approach against
cancer. Over the last decade, several agents targeting key
components of important downstream signaling have been
developed and approved by the Food and Drug Adminis-
tration (FDA) for a series of cancers. Inhibition of signaling
cascades may suppress cancer cell proliferation and sur-
vival. However, for most solid tumors, clinical efficacy
measured by overall survival benefit is modest. Despite
initial enthusiasm based on preclinical and phase II clinical
studies, subsequent phase III randomized controlled trials
were negative. However, some other randomized trials
have demonstrated clinical utility in selected patients.1
FROM BASIC SCIENCE DISCOVERY
TO CLINICAL PRACTICE
The discovery of the epidermal growth factor (EGF) and
its receptor (EGFR) in 1962 and 1978, respectively, opened
the way for a new era of molecular oncology.2 However,
successful translation of these basic research findings into
the clinic has occurred only during the last decade and
mostly for only one type of cancer, i.e., breast cancer.1
The Erbb family consists of four closely related type 1
transmembrane tyrosine kinase receptors: EGFR (or HER1),
ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4).
Each receptor comprises an extracellular domain at which
ligand binding occurs, an a-helical transmembrane seg-
ment, and an intracellular protein tyrosine kinase domain.
Ligand binding to these EGF family receptors phosphory-
lates and activates a complex intracellular signaling path-
ways network that controls a range of cellular processes
including proliferation, angiogenesis, cell cycle, survival,
and apoptosis (Fig. 1a).3
HER2 amplification and overexpression plays a central
role in initiation, progression, and metastasis of some
common cancers, including breast cancer and gastric can-
cer.1–4 HER2 status has been recognized as an important
prognostic factor. Patients with breast cancer or gastric
cancer and HER2-positive disease have significantly worse
survival than those with HER2-negative tumors.3,4 Thus,
this pivotal receptor is a potential therapeutic target.
Trastuzumab binding (Fig. 1b) inhibits HER2 signaling
pathway activity in tumor cells overexpressing HER2.
Phase III trials confirming preclinical and clinical data for
the safety and efficacy of trastuzumab independently of
robust clinicopathologic factors in both metastatic and
adjuvant setting have led to the establishment of this anti-
body as standard treatment for HER2-positive breast
cancer.1–3 However, there has been no such evidence for
any other cancer.
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CHANGING TREATMENT OF GASTRIC CANCER
Now, for the first time, positive results of a phase III trial
for the efficacy of trastuzumab are reported for gastric
cancer. Van Cutsem and colleagues have presented the
results of the ToGA study in the 2009 ASCO Annual
Meeting, May 29–June 2, in Orlando, FL.5 In this ran-
domized controlled multicenter trial, 594 patients were
randomized 1:1 at sites in Europe, Latin America, and Asia.
All these patients had HER2-positive gastroesophageal and
gastric adenocarcinoma (locally advanced, recurrent or
metastatic). They were randomized to receive trastuzumab
(Herceptin) and chemotherapy (5-fluorouracil or capecita-
bine and cisplatin) for six cycles or chemotherapy alone.
Trastuzumab was given until disease progression.
Addition of trastuzumab to chemotherapy improved
oncological outcomes. Median overall survival was signif-
icantly longer (13.5 months) in the experimental arm
(trastuzumab plus chemotherapy) than in the standard arm
(chemotherapy alone; 11.1 months) [P = 0.0048; hazard
ratio (HR) 0.74; 95% confidence interval (CI) 0.60–0.91].
Overall response rate was significantly increased by 13%
in the trastuzumab arm (P = 0.0017). Safety profile and
adverse effects data showed that trastuzumab-based regi-
men was a well-tolerated treatment; there was no difference
in symptomatic congestive heart failure between arms, and
asymptomatic left ventricular ejection fraction decreases
were reported as 4.6% in the experimental arm and 1.1% in
the chemotherapy arm.
This study provides a series of strengthens and a few
limitations. Based on evidence available from previous
positive and negative clinical trials with targeted agents,
the investigators have appropriately designed this study.
First, only HER2-positive patients were included. Tumors
from 3,807 patients were centrally tested for HER2 status:
this centralization ensures reliable assessment, quality
control, and accurate response and survival rates given that
only HER2 patients were recruited. The rate of 22% for
FIG. 1 a Ligand binding and subsequent Erbb dimer formation
initiates signaling through a complex array of intracellular pathways
that initiate and control a range of cellular processes. Dimer formation
results in the cross-phosphorylation of the dimer partners, creating
docking sites that allow the recruitment of downstream signaling
components and the formation of signaling complexes. Two key
signaling pathways activated by the Erbb family dimers are the
MAPK pathway, which stimulates proliferation, and the PI3K–Akt
pathway, which promotes tumor cell survival (see the figure). Only
signaling through these two pathways and some of the known
outcomes are shown here for simplicity. b The antibody trastuzumab
binds directly to domain IV of the extracellular region of ERBB2,
suppressing ERBB2 signaling activity, preventing cleavage of the
extracellular domain, and marking tumor cells that overexpress
ERBB2 for further immunological attack through antibody-dependent
cell-mediated cytotoxicity. GSK3b, glycogen synthase kinase 3b; NF-
jB, nuclear factor-jB; PDK1, pyruvate dehydrogenase kinase 1;
PIP2, phosphatidylinositol biphosphate; PIP3, phosphatidylinositol
triphosphate
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HER2-positive gastric cancer is similar to the HER2-
positive breast cancer rate. Second, the investigators cor-
rectly decided to use overall survival as primary endpoint
and not progression-free survival (PFS). Indeed, the
objectivity of PFS to assess response, efficacy, and clinical
utility of an experimental targeted agent has become
questionable. Cancer heterogeneity is one of the major
biological arguments against the use of PFS to measure
therapy efficacy. Although several targeted agents have
been approved by the FDA based on significant improve-
ment of PFS, more current evidence suggests that some
cancer cell populations, initially rare within the tumor,
refuse to die under treatment.6 Therefore, a nonprogressive
disease assessment by imaging techniques (no tumor size
increase) does not reflect overall response. Sensitive cancer
cells are killed, but resistant cells proliferate, developing a
uniform tumor consisting of resistant cells. These cancer
cells have the ability of metastasis, which results in no
overall survival benefit.
LIMITATIONS
The absolute benefit in response rate to trastuzumab
addition to chemotherapy was 12.8% and it resulted in a
prolongation of overall survival by 2.4 months. These data
indicate resistance to trastuzumab even among HER2-
positive selected patients. However, it is likely that,
because of less residual disease after surgery in resectable
gastric cancer, the trastuzumab therapeutic gain may be
larger in the adjuvant setting with substantial 5-year sur-
vival rate benefit. However, we should await the results of
such new adjuvant phase III trastuzumab trials.
CLINICAL PRACTICE
Although we should await details of the ToGA study full-
text publication, it appears that a new classification-based
treatment decision is now being considered. HER2 status
assessment appears essential in the diagnostic workup of
patients with locally advanced, recurrent or metastatic
adenocarcinoma of esophagogastric junction and stomach.
Although a similar trastuzumab effect is likely in the adju-
vant setting, considering also the HER2-positive breast
cancer experience, no trastuzumab use for early HER2-
positive gastric cancer can be suggested before the com-
pletion of new trastuzumab-based phase III adjuvant trials.
PERSPECTIVES FOR OVERCOMING
RESISTANCE
Resistance to molecular targeting therapy is currently
the cause of treatment failure in cancer. Despite
trastuzumab-containing treatment a substantial proportion
of HER2-positive breast cancer patients either recur in the
adjuvant setting or progress after initial response and die of
the disease. Similarly, the absolute additional response rate
to trastuzumab among HER2-positive advanced gastric
cancer in the ToGA study is small: 12.8%. Given that
HER2-positive accounts for approximately 25%, only
3.12% of all gastric cancer patients can benefit from trast-
uzumab treatment.
How could this intrinsic or acquired resistance be
overcome? Research strategies are focused on the devel-
opment of both novel drugs and molecular markers beyond
HER2 expression for tailoring the best treatment to indi-
vidual patients. There are two main directions: first, better
understand of Erbb signaling pathways and trastuzumab
mechanisms of actions and resistance; second, exploring
the role of other signaling pathways including Wnt/b-
catenin, TGF-b/SMADs, and other pathways involved in
cancer may lead to understanding of intracellular signaling
pathways network in various cancer types.
The first, more realistic, approach has already led to
clinical applications. Improved insights into the biology of
the Erbb family have led to additional active anti-HER2
therapies. New strategies against HER2 include Erbb
tyrosine kinase inhibitors (TKIs), heat shock protein 90
inhibitors, Erbb dimerization inhibitors, and antibody–
chemotherapy conjugates. All of these approaches have
shown substantial clinical activity in patients who have
progressed on trastuzumab treatment.3 TKIs-based target-
ing of HER2, preventing signal transduction of both the
Ras–RAF1 MAPK and PI3K–Akt pathways, led to an
increase in apoptosis and a decrease in cellular prolifera-
tion (Fig. 1).
The most clinically advanced anti-HER2 TKI is lapati-
nib (Tykerb; GlaxoSmithKline), a dual HER2 and EGFR
TKI small molecule. Based on a pivotal phase III study,
lapatinib in combination with capecitabine has been
approved by the FDA for use in patients with advanced
HER2-positive breast cancer who have previously received
trastuzumab.3 Therefore, lapatinib alone or in combination
with trastuzumab, which was shown to be superior to a
single agent, are potential effective therapies to overcome
trastuzumab resistance in HER2-positive gastric cancer.3
Mutations in signaling components downstream of the
initiating Erbb dimer and several interconnections between
the two main signaling pathways MAPK and PI3 K-Akt of
Erbb may bypass therapy suppression and are plausible
explanations for resistance to trastuzumab in HER2-positve
breast cancer and possibly also gastric cancer. Multitar-
geted approaches have been evaluated and provided
promising results; for example, encouraging findings
have been reported with inhibition of mToR activity or
the addition of a dual inhibitor of both mToR and
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Although still in its infancy, the second approach to
predict complex signaling pathways interactions, including
Erbb signaling, if successful, might revolutionize treatment
of gastric cancer, breast cancer, and other solid tumors.
Given the current strong evidence that multiple genetic
alterations and several signaling pathways are dysregulated
in solid cancers, one of the most rational approaches is to
inhibit these pathways.7 Combining targeted agents and
considering crosstalk between pathways and bypass of
targeted agents as well as predictors of response might lead
to highly effective therapies.7
However, there are many challenges. Cancer heteroge-
neity is reflected by variation in deregulated pathways
among patients with the same tumor, tumor–node–metas-
tasis (TNM) staging, and clinicopathologic factors. At
present there is no standard method to identify either which
pathways are dysregulated or how they interact in individ-
ual patients. The new era of personalized medicine provides
major promises. One approach is to integrate personal
genomics and clinicopathologic and treatment data into
sophisticated in silico models to predict genotype–pheno-
type map in cancer.8 Rapid advances in molecular systems
biology and future cheaper whole-genome cancer data
scans are innovative exciting developments towards the
development of novel response predictors and a new gen-
eration of multitargeted agents.8,9 The new era of
personalized cancer care is here, but multiple challenges
including major funding requirements and reliable data
analysis make the translation of personalized research
approaches into clinical medical practice difficult.10
CONCLUSIONS
HER2 status should now be included in diagnostic
makeup of patients with advanced gastric cancer. Addition
of trastuzumab to chemotherapy improves overall survival
and is a new standard treatment for patients with locally
advanced, recurrent or metastatic HER2-positive disease.
Although this efficacy is likely in the adjuvant setting, an
evidence-based decision on trastuzumab use in early
gastric cancer requires the completion of new adjuvant
phase III trials.
Resistance to current therapies is a major challenge.
Lapatinib and other novel antibodies or TKIs tested in
clinical trials for HER2-positive breast cancer might also
prove effective in trastuzumab-resistant HER2-positive
gastric cancer. However, such Erbb-based approaches have
less application in HER2-negative disease, which accounts
for the majority of patients with gastric cancer or breast
cancer. Understanding genotypic–phenotypic cancer diver-
sity and signaling feedback loops as well as developing
reliable methods to screen for identifying dysregulated
signaling pathways in individual patients is a rational and
exciting approach. If successful, such comprehensive
approaches using molecular systems biology and future
whole-genome cancer data scans may result in the discovery
of novel multitargeted therapies tailored to individual
patients on the basis of novel predictors of response to
combined therapies.
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